Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Viewpoint - Larimar Therapeutics, Inc. is actively participating in the 44th Annual J.P. Morgan Healthcare Conference, indicating its commitment to engaging with investors and showcasing its developments in rare disease treatments [1]. Company Overview - Larimar Therapeutics, Inc. (Nasdaq: LRMR) is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases [3]. - The company's lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia [3]. - Larimar plans to utilize its intracellular delivery platform to design additional fusion proteins targeting other rare diseases characterized by deficiencies in intracellular bioactive compounds [3]. Event Details - The presentation at the J.P. Morgan Healthcare Conference is scheduled for January 14, 2026, from 9:00 to 9:40 AM PST [2]. - A webcast of the presentation will be available, with a replay accessible for 30 days on Larimar's website [2].